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Insulin resistance and elevated glucagon levels result
in nonsuppressible hepatic glucose production and
hyperglycemia in patients with type 2 diabetes. The
CREB coactivator complex controls transcription of
hepatic gluconeogenic enzyme genes. Here, we
show that both the antidiabetic agent metformin
and insulin phosphorylate the transcriptional coacti-
vator CREB binding protein (CBP) at serine 436 via
PKCi/l. This event triggers the dissociation of the
CREB-CBP-TORC2 transcription complex and
reduces gluconeogenic enzyme gene expression.
Mice carrying a germline mutation of this CBP phos-
phorylation site (S436A) demonstrate resistance to
the hypoglycemic effect of both insulin and metfor-
min. Obese, hyperglycemic mice display hepatic
insulin resistance, but metformin is still effective in
treating the hyperglycemia of these mice since it
stimulates CBP phosphorylation by bypassing the
block in insulin signaling. Our findings point to CBP
phosphorylation at Ser436 by metformin as critical
for its therapeutic effect, and as a potential target
for pharmaceutical intervention.
INTRODUCTION
Blood glucose levels aremaintained within a narrow range by the
liver through the opposing actions of insulin and glucagon (Bid-
dinger and Kahn, 2006; Kitamura and Accili, 2004; Saltiel and
Pessin, 2002). Impaired insulin signaling together with elevated
glucagon levels result in hyperglycemia and subsequent type 2
diabetes mellitus (Baron et al., 1987; Dunning and Gerich, 2007).
Inappropriate hepatic glucose production is the major cause of
hyperglycemia in these patients.
Glucagon promotes hepatic glucose production by activating
cAMP-PKA signaling that induces the phosphorylation of tran-
scription factor CREB at Ser133 and dephosphorylation ofTORC2 (also referenced as CRTC2), leading to the formation of
the transcriptional CREB-CBP-TORC2 complex (Ravnskjaer
et al., 2007; Xu et al., 2007) on a cAMP response element site
(CRE). This complex increases transcription of the Ppargc1
(also termed as PGC-1a, the protein product is PGC-1a) gene
and its downstream target genes such as the rate-limiting gluco-
neogenic enzyme genes, phosphoenolpyruvate carboxykinase
(Pck1) and glucose-6-phosphatase (G6pc) (Koo et al., 2005;
Ravnskjaer et al., 2007). Insulin counteracts the action of
glucagon on hepatic gluconeogenesis mainly at the transcrip-
tional level through PGC-1a (Yoon et al., 2001). The CREB-
CBP-TORC2 complex binds to CRE site of Ppargc1 through
transcription factor CREB, and both CBP and TORC2 are coac-
tivators for CREB.
CBP was originally identified as a CREB binding protein that
interacts with the CREB KID domain (Radhakrishnan et al., 1997;
Goodman and Smolik, 2000). CBP, which contains intrinsic
histone acetyltransferase (HAT) activity, also interacts with
various components of the basal transcription machinery such
as TATA box binding protein (TBP), TFIIB and with cell-specific
transcription factors (Goodman and Smolik, 2000). TORC2, in
contrast, binds to the bZIP domain of CREB in a phosphoryla-
tion-independent manner, and augments CRE-dependent tran-
scription (Conkright et al., 2003). The phosphorylation of CREB
at Ser133 is critical for the recruitment of CBP to CREB. However,
both glucagon and insulin were documented to stimulate phos-
phorylation at this site (Koo et al., 2005). We have previously
shown that insulin stimulates CBP phosphorylation at Ser436
and a germline mutation of this CBP phosphorylation site
(S436A) in a mouse model leads to inappropriate activation of
gluconeogenesis and glucose intolerance (Zhou et al., 2004).
Insulin also stimulates the phosphorylation of TORC2 at Ser171
leading to its nuclear exclusion and degradation (Dentin et al.,
2007). It remains unclear, however, which insulin signaling event
determines the disassembly of CREB-CBP-TORC2 complex.
Metformin was introduced clinically in the 1950s and is widely
used as a first line treatment for patients with type 2 diabetes
mellitus. Metformin improves glucose metabolism mainly by
suppressing hepatic glucose production (Hundal et al., 2000),
but its mechanism of action remains elusive. Metformin hasCell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc. 635
been reported to stimulate the phosphorylation and nuclear
exclusion of TORC2 (Shaw et al., 2005); however, since
TORC2 is O-glycosylated at Ser171 in the insulin resistant state
(Dentin et al., 2008), phosphorylation at this site is unlikely to be
the mechanism of action of metformin in patients with diabetes.
Here we show that CBP phosphorylation at Ser436 by insulin
and metformin requires aPKCi/l, which has been previously
reported to mediate insulin induced lipogenesis in the liver
(Matsumoto et al., 2003). This event is essential for the dissocia-
tion of CREB-CBP-TORC2 complex. Only metformin is able to
stimulate CBP phosphorylation in a mouse obesity model of
insulin resistance, suggesting a mechanism for its therapeutic
effect.
RESULTS
The Essential Role of CBP in cAMP-PKA Mediated
Activation of Gluconeogenic Gene Expression
In response to the argument that recruitment of CBP to CREB
target genes is unnecessary for induction of the gluconeogenic
program (Koo et al., 2005), we examined the potential role of
CBP in mediating CREB target gene expression. First, we
used a cAMP response element (CRE)-luciferase reporter assay
in a transiently transfected hepatocyte cell line. Forskolin (FSK)
treatment or cotransfection with an expression vector contain-
ing the catalytic subunit of PKA increased luciferase activity
by approximately 5-fold (Figure 1A). RNAi-mediated CBP
knockdown abolished the effects of both PKA and FSK on the
CRE-responsive reporter. We next tested GAL4 fusion
constructs of full length CREB cDNA and TORC2 cDNA on
a GAL4 reporter. RNAi-mediated knockdown of CBP protein
levels blocked the effect of cotransfected PKA on either fusion
construct (Figures 1B and 1C); additionally, knock-down of
CBP blocked the effect of cotransfected TORC2 (Figure 1B).
FSK stimulation of Ppargc1a, Pck1 and G6pc mRNA levels
was also significantly suppressed by adenoviral shRNA-medi-
ated knockdown of CBP in primary hepatocyte cells
(Figure 1D). Furthermore, adenoviral shRNA-mediated knock-
down of CBP protein in the liver of fasted mice decreased
both glucose levels (Figure 1E) and the expression of gluconeo-
genic genes (Figure 1F). The above data indicate that CBP plays
an essential role in mediating CREB target gene expression in
the hepatocyte.
CBP Phosphorylation at Ser436 by Insulin and
Metformin Is Mediated through Atypical Protein
Kinase C
We previously reported that insulin regulates hepatic gluconeo-
genesis through CBP phosphorylation at Ser436 (Zhou et al.,
2004). This CBP phosphorylation site is conserved in eukaryotic
species (Figure 2A), suggesting that phosphorylation at this site
may be a universal mechanism for controlling CBP responsive
gene transcription. We therefore developed a phospho-specific
CBP antiserum to this site. In a hepatocyte cell line, insulin stim-
ulated CBP phosphorylation in a rapid (within 5 min) (Figure 2B,
top) and a concentration-dependent manner (see Figure S1
available with this article online). In fasted mice, insulin stimu-
lated CBP phosphorylation dramatically in liver extracts, and636 Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc.treatment with alkaline phosphatase eliminated the phospho-
CBP signal (Figure 2B, bottom). This antiserum was proven to
be specific for phosphorylation of this site and does not cross-
react with the related p300 protein (Figures S2 and S3). The
PI3 kinase inhibitor (LY294002) blocked insulin mediated CBP
phosphorylation in hepatocyte cells (Figure S4), indicating that
insulin stimulates CBP phosphorylation through the PI3K
pathway.
CBP Ser436 is part of a potential consensus PKC phosphory-
lation site (435-ASDKR-439) (Figure 2A). Interestingly, the related
p300 protein contains the identical amino acid sequence as CBP
in the region, except that a glycine residue (Gly422) is substituted
for the serine residue (Ser436). This difference is suggested to
affect the length of the a4 helix in theC/H1 domain of the proteins
(De Guzman et al., 2004). To define the class of PKC is respon-
sible for CBP phosphorylation at Ser436, we treated hepatocyte
cells with two PKC inhibitors. The nonisoform selective PKC
specific inhibitor, Ro31-8220, blocked insulin induced CBP
phosphorylation; however, an inhibitor of classical and novel
PKC isoforms, Go6976, had no effect on insulin induced CBP
phosphorylation (Figure 2C, top). These data suggest that insulin
mediates CBP phosphorylation through atypical PKCs (aPKCs).
Atypical PKCs (z, i/l) are conserved across species and are
ubiquitously expressed in most tissues (Selbie et al., 1993; Aki-
moto et al., 1994), and aPKCi and l are human/mouse orthologs
(Nishizuka, 1995). As shown in Figure 2C (bottom), RNAi-medi-
ated knockdown of aPKCi/l in hepatocyte cells blocked CBP
phosphorylation by insulin; in contrast, RNAi-mediated knock-
down of aPKCz had no effect on insulin induced CBP phosphor-
ylation, suggesting that this aPKCi/l mediates insulin-induced
CBP phosphorylation. Western blot analysis of brain and liver
tissue from mice demonstrates comparable amounts of
aPKCi/l in the liver and brain (Figure 2D); however, consistent
with a previous finding (Selbie et al., 1993), there is significantly
less aPKCz in the liver than in the brain. Further, knockdown of
aPKCi/l in the liver using an adenoviral shRNA blocked insulin
induced CBP phosphorylation in the liver (Figure 2D, bottom).
In cells, transfection of increasing amount of a CMV expression
vector containing aPKCi/l led to CBP phosphorylation
(Figure 2E, top). In an in vitro phosphorylation assay, purified
aPKCi/l phosphorylated CBP of liver tissue extract from fasted
wild-type mice, but not from CBP mutant (S436A) mice
(Figure 2E, bottom). Finally, mice injected with an adenoviral
aPKCi/l shRNA exhibited fasting hyperglycemia (Scrambled
shRNA versus CBP shRNA: 109 ± 3.3 versus 142 ± 2.9 mg/dl,
p < 0.05) and glucose intolerance (Figure 2F), supporting the
notion that aPKCi/l phosphorylates CBP and modulates
glucose metabolism (Chen et al., 2002).
The AMPK activator, 5-aminoimidazole-4-carboxamide-1-
b-D-riboside (AICAR), also activates aPKCs (Chen et al., 2002),
which prompted us to evaluate the effect of AICAR and another
AMPK activator, metformin, on CBP phosphorylation. Both
AICAR and metformin stimulated CBP phosphorylation in
a hepatocyte cell line (Figure 3A), and in contrast to insulin, did
not cause phosphorylation of either AKT or GSK3. The antidia-
betic effect of metformin requires AMP-activated protein kinase
(AMPK) (Zhou et al., 2001; Shaw et al., 2005), and AMPK can
activate aPKCs, which increase glucose transport in muscle
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Figure 1. CBP Is Essential to the Activation of cAMP-PKA Responsive Genes in Hepatocyte Cells
(A) PKA or forskolin (FSK, 3h) stimulates cotransfected CRE-luciferase reporter activity. RNAi mediated CBP knockdown (insert) abolishes PKA and FSK effects.
Scr, scrambled RNAi.
(B and C) (B) GAL4-CREB (full length) and GAL4-TORC2 (C) transactivation assays. Both PKA and TORC2 effects are abolished upon CBP knockdown.
(D–F) (D) Adenoviral shRNA-mediated knockdown of CBP suppresses FSK stimulated transcription of endogenous Ppargc1a, Pck1 andG6pc in mouse primary
hepatocyte cells. Primary hepatocyte cells were cultured in serum-free DMEM, and incubated with vehicle or 10 uM FSK for 6 hr before the harvest. Mice with
adenoviral shRNA-mediated CBP knockdown in liver demonstrates lower fasting blood glucose (E) and decreased gluconeogenic gene expression (F). mRNA
measurements are normalized to 18S rRNA levels. Means ± SEM are shown. Asterisk (*) signifies that groups (CBP knockdown versus control) with same treat-
ment are significantly different (p < 0.05).(Chen et al., 2002). We cotransfected increasing amounts of an
AMPK expression vector in hepatocyte cells, and this resulted
in an increase in CBP phosphorylation (Figure 3B), and either
metformin treatment or AMPK overexpression led to the CBP
phosphorylation even in the presence of the PI3K inhibitor
LY294002 (Figure 3C). In contrast, RNAi-mediated knockdown
of aPKCi/l blocked the ability of metformin or AMPK to
stimulate CBP phosphorylation (Figure S5 and Figure 3D,
respectively). In vivo, metformin like insulin stimulated CBP
phosphorylation in the mouse liver (Figure 3E) and this effect
was blocked in mice injected with adenoviral shRNA against
aPKCi/l.Phosphorylation plays an important role in activating PKC
activity (Parekh et al., 2000; Newton, 2003). For this reason, we
examined the phosphorylation status of aPKCi/l. Metformin
and AMPK overexpression stimulated phosphorylation of
aPKCi/lat Thr403andThr555,which are located in theactivation
loop of kinase domain and in the turn motif, respectively (Figures
3A-3C and 3F). Phosphorylation at Thr403 has been shown to be
critical for kinase activity of aPKCi/l (Messerschmidt et al., 2005).
ThePI3K inhibitor had noeffect onAMPK inducedaPKCi/lphos-
phorylation (Figure 3C). Thus, metformin, AMPK and insulin
mediate CBP phosphorylation by activated aPKCi/l through
increasing its phosphorylation at Thr403 and Thr555.Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc. 637
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Figure 2. Insulin Induces CBP Phosphorylation through aPKC
(A) CBP phosphorylation site at Ser436 (mouse) is conserved across eukaryotic species.
(B) Insulin induces CBP phosphorylation in a time-dependent manner in H4IIEC3 cells (top). Hepatic CBP phosphorylation is detected after insulin administration
in fasted mice and alkaline phosphatase treatment of hepatic lysates removes phosphorylation (bottom). Each lane represents an individual mouse sample.
(C) Nonisoform selective PKC inhibitor Ro31-8220 (Ro), but not Go6976 (Go; inhibitor of classical and novel PKC isoforms) inhibits insulin stimulated CBP phos-
phorylation (top). RNAi mediated aPKCi/l knockdown blocks insulin stimulated CBP phosphorylation (bottom).
(D) Relative amount of aPKCs in brain and liver (top), adenoviral shRNA-mediated CBP knockdown in liver blocked insulin induced CBP phosphorylation (bottom).
(E) Overexpression of aPKCi/l stimulated CBP phosphorylation (top). Only immunoprecipitated CBP from wild-type mouse (fasted) liver extracts can be phos-
phorylated by aPKCi/l in the presence of ATP (bottom). (F) Knockdown aPKCi/l by adenoviral shRNA in liver resulted in glucose intolerance (2 g / kg ip in 8 h
fasted mice). Means ± SEM are shown. Asterisk (*) signifies p < 0.05 as compared with control at each time point. Scr, scrambled RNAi.Control of Hepatic Gluconeogenesis through
Phosphorylation of CBP at Ser436 by Insulin
and Metformin
Insulin stimulates CREB phosphorylation at Ser133 (Koo et al.,
2005), and stimulates TORC2 phosphorylation at Ser171 (Koo
et al., 2005; Shawet al., 2005). Alternatively, we provide evidence
that insulin stimulates CBP phosphorylation at Ser436
(Figure 2B). It is important, therefore, to understand the relative
importance of phosphorylation of members of the CREB-CBP-
TORC2 complex. Since insulin counteracts the action of
glucagon on hepatic gluconeogenesis mainly at the transcrip-
tional level through the transcriptional coactivator PGC-1a
(Yoon et al., 2001), we evaluated the binding states of CREB,
CBP and TORC2 to promoters of Ppargc1a and Pck1 in liver
tissue from fasted and refed mice. In this study, increased CBP
phosphorylation and TORC2 degradation in refed mice
(Figure 4A) coincided with the absence of both CBP and638 Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc.TORC2 from the Ppargc1a and Pck1 promoters as compared
to fasted mice (Figure 4B). However, CREB binding to these
promoters did not change, suggesting that the binding of coacti-
vators (CBP and TORC2) to the complex determines Ppargc1a
and Pck1 gene expression during fasting and refeeding.
To explore further the phosphorylation and promoter occu-
pancy of CREB, CBP and TORC2 in the control of hepatic
glucose production, we conducted insulin time course experi-
ments in fasted wild-type mice. In this experiment, blood
glucose levels fell sharply after intraperitoneal administration of
insulin within the first 30 min, and subsequently blood glucose
levels began to rise (Figure 4C, insert). Serum insulin level
reached its peak at 10 min after intraperitoneal insulin injection;
we then observed robust glucagon secretion which reached
a peak at 30 min after insulin exposure in response to the insulin
induced hypoglycemia (Figure 4C). Hepatic mRNA expression
pattern of Ppargc1a and Pck1 were very similar to the changes
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Figure 3. Metformin Stimulates CBP Phosphorylation through aPKCi/l
(A)Metformin, AICAR, insulin and (B) AMPK overexpression stimulate CBP phosphorylation. (C) PI3K inhibitor LY294002 fails to inhibit CBP phosphorylation. CBP
phosphorylation is blocked by RNAi or adenoviral shRNA-mediated knockdown aPKCi/l in hepatocyte cells (D) or in liver (E). (F) Metformin treatment (5 hr) in
hepatocyte cells stimulates hepatic CBP phosphorylation in a concentration-dependent manner.in blood glucose levels (Figure 4D). In liver tissue, the extent of
CREB phosphorylation at Ser133 remained unchanged during
the entire experiment (Figure 4E). These data are consistent
with the notion that both insulin and glucagon induce phosphor-
ylation of CREB at Ser133 (Koo et al., 2005). Insulin stimulated
CBP phosphorylation within 10 min of treatment; at subsequent
time points, CBP phosphorylation decreased (Figure 4E). The
reduction of CBP phosphorylation at later time points after
insulin treatment accompanied by robust glucagon secretion
indicates glucagon may be responsible for the dephosphoryla-
tion of CBP (Figures 4C and 4E). Indeed, pretreatment of
hepatocyte cells with forskolin blocked insulin-induced CBP
phosphorylation (Figure S6), and the phosphatase inhibitors
okadaic acid and calyculin A blocked the effect of forskolin
leading to increased CBP phosphorylation (Figures 4F and S7).
Consistent with previous studies (Dentin et al., 2007), the peak
of TORC2 phosphorylation occurred at a later time (30 min)
than peak CBP phosphorylation after insulin exposure, and
TORC2 phosphorylation led to its degradation (Figure 4E).
Chromatin immunoprecipitation (ChIP) assay of hepatic tissue
was then used to determine the occupancy of CREB, CBP and
TORC2 on the CRE site of the Ppargc1a and Pck1 gene
promoters. The binding of CBP and TORC2 started to decrease10 min after insulin exposure and was absent from the Ppargc1a
and Pck1 promoters 30 min after insulin treatment. In contrast to
TORC2, however, CBP returned to these promoters at 60 min
(Figure 4G), coincidingwith an4-fold increase inmRNA expres-
sion of Ppargc1a and Pck1 (Figure 4D). No change in CREB
binding to the Ppargc1a and Pck1 promoters was observed
(Figure 4G). These data strongly support the critical role for CBP
in transcriptional regulation of gluconeogenic enzyme genes.
It is important to note that CBP phosphorylation was inversely
correlated with CBP occupancy on Ppargc1a and Pck1
promoters, suggesting that CBP phosphorylation at Ser436
might play an important role in dissociating and reforming the
CREB-CBP-TORC2 complex after insulin treatment. To test
this hypothesis, we compared wild-type and mutant CBP
expression vectors in transient transfection studies. We found
that insulin treatment decreased the activity of a CRE-responsive
reporter in cells cotransfected with wild-type CBP (p < 0.01), but
not with CBP mutants (Figure 5A). Insulin action on the CRE-
responsive reporter was abolished by treatment with a PI3
kinase (PI3K) inhibitor (LY294002) (Figure S8), suggesting that
in this context insulin acts through the PI3K pathway. Metformin,
like insulin, decreased CRE-mediated luciferase activity in cell
cultures cotransfected with wild-type CBP (p < 0.01), but notCell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc. 639
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Figure 4. Control of Hepatic Gluconeogenesis Is through CBP Phosphorylation by Insulin
(A and B) (A) CBP phosphorylation increases and TORC2 protein levels decrease in hepatic lysates from fasted (16 hr) or refed mice (2 hr), accompanied by (B)
reduced CBP and TORC2 occupancies on the CREs of Ppargc1a and Pck1 promoters.
(C) Serum insulin, glucagon and blood glucose levels (inset) in fasted mice during the insulin time course experiment.
(D) Relative mRNA levels of Ppargc1a and Pck1 increase as glucose recovers after insulin induced hypoglycemia. (E) Insulin rapidly stimulates CBP phosphor-
ylation and TORC2 degradation in 16 hr fasted mice.
(F) Forskolin antagonizes insulin induced CBP phosphorylation which is blocked by okadaic acid in hepatocyte cells.
(G) The change in CBP occupancy and reduced TORC2 onCREs ofPpargc1a andPck1 promoters in liver ChIP assays. Each lane represents an individual mouse
sample (A, B, E, G). Means ± SEM are shown (C and D).CBPmutant expression vectors (Figure 5B). The above data indi-
cate that Ser436 of CBP plays a key role in mediating the actions
of insulin and metformin in the regulation of gluconeogenic
enzyme gene expression.
To examine this hypothesis more directly, a hepatocyte cell
line was cotransfected with wild-type or mutant (S436A) CBP
and TORC2 expression vectors in a GAL4-CREB (full length)
reporter assay. Both insulin and metformin treatment decreased
reporter activity significantly (p < 0.01) in cells cotransfected with
wild-type CBP (Figure 5C). However, the effect of insulin and
metformin on GAL4-CREB (full length) reporter activity was abol-
ished in cells cotransfected with mutant (S436A) CBP. These
data indicate that Ser436 of CBP plays a dominant role in the
action of insulin and metformin on GAL4-CREB complex in this
reporter assay and raise the possibility that the phosphorylation
of CBP at Ser436 is the key event leading to dissociation of both
CBP and TORC2 from the CREB-CBP-TORC2 complex.
TORC2 coimmunoprecipitated with CBP (Ravnskjaer et al.,
2007), indicating that TORC2 might associate with CBP as640 Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc.well in the CREB-CBP-TORC2 complex. To test this possibility,
we cotransfected wild-type or CBP mutants into a hepatocyte
cell line with TORC2 and a GAL4-CREB construct (1-280 aa),
which lacks the TORC2 binding domain (Figure 5D). We found
that TORC2 significantly enhanced reporter activity when co-
transfected with wild-type CBP and had an even greater effect
when cotransfected with mutant (S436A) CBP. No effect on
reporter activity was found with cotransfection of mutant
(S436D) CBP, which mimics phosphorylated CBP (Figure 5D).
These results suggest that TORC2 associates directly with
CBP in the CREB-CBP-TORC2 complex. To examine this
further, a hepatocyte cell line was cotransfected wild-type or
mutant (S436A) CBP and either wild-type or mutant TORC2
(S171A)-a functional nuclear resident, nonphosphorylated form
of TORC2 (Koo et al., 2005) in a GAL4-CREB (full length)
reporter assay. Metformin antagonized the stimulatory effect
of PKA and CBP, even in the presence of mutant TORC2
(S171A), while no antagonism was observed with CBP S436A
(Figure 5E).
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Figure 5. Insulin and Metformin Modulate the Activation of cAMP-PKA Responsive Genes through CBP Phosphorylation
(A) Insulin and metformin (B) fail to suppress PKA stimulated CRE responsive transcription in the presence of CBP S436 mutants in H2.35 cells.
(C) Insulin and metformin suppress PKA and TORC2 stimulated GAL4-CREB (full length) transcription in the presence of wild-type CBP, but not of CBP S436A
mutant in H4IIEC3 cells.
(D) GAL4 fused to a shortened CREB (1-280 aa), which has the CBP binding domain but lacks the TORC2 interacting domain requires CBPWT or CBP S436A for
TORC2 mediated transcription stimulation. CBP S436 phosphorylation mimicked by CBP S436D mutant abolishes TORC2 mediated stimulation. EV, empty
control vector.
(E) Metformin reduction of GAL4-CREB transactivation requires intact Ser436 on CBP and is independent of TORC2S171 phosphorylation.Bars =means ±SEM.
Asterisk (*) signifies p < 0.01 as compared with other PKA transfected groups.
(F) Hepatic lysates from overnight fasted wild-type mice or CBP mutant mice were immunoprecipitated with either a CBP antibody (upper panel) or CREB anti-
body (lower panel), immunoprecipitates were treated with or without aPKCi/l kinase, washed and blotted with indicated antibody.To support the hypothesis that CBP phosphorylation leads
to the dissociation of the CREB-CBP-TORC2 complex, we
conducted in vitro phosphorylation assays using a purified
aPKCi/l kinase preparation after immunoprecipitation of liver
extracts with either a CBP or CREB antibody (Figure 5F). Without
aPKCi/l kinase treatment, CREB and TORC2 coimmunopreci-
pated with either wild-type or mutant CBP (upper panel); and
either wild-type or mutant CBP and TORC2 coimmunopreci-
pated with CREB (lower panel). After aPKCi/l kinase treatment,
in contrast, only TORC2 coimmunoprecipitated with wild-type
CBP (upper panel); and both wild-type CBP and TORC2 dissoci-ated from CREB (lower panel). However, aPKCi/l kinase treat-
ment of mutant CBP liver extract with either antibody demon-
strated an intact CREB-CBP-TORC2 complex. These results
strongly support a model where CBP phosphorylation at
Ser436 is the triggering event for dissociation of the CREB coac-
tivator complex.
To support further this model, we determined the binding
states of CBP and TORC2 in CBP S436A mutant mice treated
with insulin or metformin. As expected, both insulin and metfor-
min stimulated CBP phosphorylation in the liver of wild-type
mice, but not in the liver of CBP mutant mice (Figure 6A). AsCell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc. 641
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Figure 6. CBP S436A Mutation Perturbs In Vivo Actions of Insulin and Metformin
(A and B) (A) Insulin andmetformin stimulate CBP phosphorylation inWT but not CBP S436Amouse liver. (B) CBP and TORC2 occupancies to CREs of Ppargc1a
and Pck1 promoters are reduced by insulin or metformin in WT but not CBP S436A mouse liver. Each lane represents an individual mouse sample (A and B).
(C) Cotransfection with S436Amutant but notWTCBP retains GFP-TORC2 in the nucleus after insulin or metformin treatment. H4IIEC3 cells were pretreated with
forskolin plus 200 nM dexamethasone for 5 hr, then treated with insulin or metformin for 3 hr.
(D) Glucose infusion rate and glucose disposal rate during a hyperinsulinemic euglycemic clamp experiment. (**p < 0.01; NS, not significant).
(E) Hepatic glucose production in the basal period and in response to insulin infusion during clamp experiment (n = 4) (**p < 0.01 as compared with control mice
during the clamp).
(F) Insulin tolerance test (0.35 unit/kg ip in 4 hr fasted WT and CBP S436A mice [n = 5]).
(G) Pyruvate tolerance test (2 g/kg) in 6 h fasted WT and CBPS436A mice (n = 4). (H) Metformin tolerance test in 10 h fasted WT and CBPS36A mice (n = 7).
*p < 0.05, **p < 0.01 as compared with control mice at the same time point (F, G, and H). Means ± SEM are shown (D–H).illustrated in Figure 6B, treatment with insulin or metformin led to
CBP and TORC2 dissociation from the Ppargc1a and Pck1
promoters in wild-type mice (Figure 6B, left). If the phosphoryla-
tion of CBP by insulin or metformin leads to dissociation of the
CREB-CBP-TORC2 complex, then mutation of CBP (S436A)
should prevent dissociation of the CREB-coactivator complex
by these agents. We next preformed a ChIP assay in liver tissue
from CBP mutant mice. In these mutant mice, neither insulin nor
metformin affected CBP or TORC2 occupancy on the Ppargc1a
and Pck1 promoter (Figure 6B, right) even though TORC2 was
also phosphorylated in the CBP mutant mice by either insulin
or metformin (Figure S9). To provide further evidence to support
the hypothesis that CBP phosphorylation triggers the dissocia-
tion of TORC2 from the CREB coactivator complex, hepatocyte
cells were cotransfected with GFP-TORC2 and either wild-type642 Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc.or mutant CBP S436A. Both GFP-TORC2 and CBPs are equally
expressed in the hepatocyte cells in each group (data not
shown). Coexpression of wild-type CBP with GFP-TORC2 re-
sulted in nuclear localization of GFP-TORC2 after exposure to
forskolin and its nuclear export after insulin or metformin treat-
ment confirming previous reports (Koo et al., 2005; Shaw et al.,
2005). Coexpression of CBPS436A and GFP-TORC2, in
contrast, blocked nuclear export of GFP-TORC after these treat-
ments (Figure 6C). These data pinpoint the crucial role of CBP
phosphorylation in controlling the dissociation of the CREB
coactivator complex.
The above results offer an explanation for enhanced gluco-
neogenic enzyme expression, inappropriate activation of gluco-
neogenesis, and insulin intolerance in mutant (S436A) CBP mice
(Zhou et al., 2004). Fasting blood glucose and serum insulin
levels were elevated in CBP mutant mice, indicating the insulin
resistance in CBPmutant mice (Zhou et al., 2004). During the hy-
perinsulinemic euglycemic clamp experiment, glucose infusion
rates were significantly reduced in CBP mutant mice
(Figure 6D, left), and glucose disposal rates were somewhat
lower, but not statistically different in CBP mutant versus wild-
type mice (Figure 6D, right). In response to insulin, hepatic
glucose production was completely suppressed in wild-type
control while a significant amount of glucose production re-
mained in CBP mutant mice (Figure 6E). Moreover, CBP mutant
mice exhibited both insulin and pyruvate intolerance (Figures 6F
and 6G). The above data clearly demonstrate significant hepatic
insulin resistance in CBP mutant mice. CBP phosphorylation
was stimulated by metformin both in vitro and in vivo (Figures
3A, 3C, 3E, and 3F), and metformin antagonized wild-type CBP
in luciferase assays (Figures 5B, 5C, and 5E). As its therapeutic
effect in diabetes patients occurs mainly through suppressing
hepatic glucose production (Hundal et al., 2000), we attempted
to determine its effects on fasting blood glucose in CBP S436A
mutant and wild-type mice. Treatment with metformin through
intraperitoneal injection (ip) decreased blood glucose levels
significantly in wild-type mice (Figure 6H). However, metformin
treatment had no effect on the blood glucose levels in CBP
mutant mice (Figure 6H). These data clearly demonstrate that
CBP Ser436 is the target site of metformin action.
Metformin Not Insulin Promotes CBP Phosphorylation
in Obese Mice
Metformin phosphorylates TORC2 at Ser171 and leads to its
nuclear exclusion (Koo et al., 2005; Shaw et al., 2005); however,
the same group has reported that TORC2 is O-glycosylation at
Ser171 in the insulin resistance state which would preclude
phosphorylation (Dentin et al., 2008). This finding argues that
Ser171 of TORC2 can not be the principle site of metformin
action in patients with type 2 diabetes (Shaw et al., 2005).
Furthermore, metformin antagonized the stimulatory effect of
PKA and CBP, even in the presence of mutant TORC2
(S171A), but not with CBPS436A cotransfection, suggesting
that CBP phosphorylation is the main site of metformin action
in controlling hepatic glucose production. If this is the mecha-
nism, CBP must be phosphorylated by metformin in the setting
of insulin resistance. We, therefore, placed mice on a high-fat
diet (HFD) for 4-month which induced hepatic insulin resistance
as demonstrated by fasting hyperglycemia (wild-type versus
mutant: 122.5 ± 6.4 versus 145.3 ± 11.5 mg/dl, p < 0.05) and
the inability of insulin to mediate AKT phosphorylation
(Figure 7A). In mice on a HFD, CBP phosphorylation wasminimal
after insulin treatment compared to wild-type mice fed a normal
chow diet (Figures 7A and 7B). In contrast and consistent with its
ability to suppress hepatic glucose production in diabetes,
metformin stimulated hepatic CBP phosphorylation in HFD fed
mice to the same extent as mice fed a normal diet. In wild-type
mice on a HFD, metformin lowered the blood glucose almost
to the same degree as in wild-type mice fed a normal chow
diet (compare Figures 6H and 7C). Again, metformin treatment
had no effect on the blood glucose levels in CBP mutant mice.
These results suggest a plausible mechanism for the therapeutic
effect of metformin, which at molecular level results in CBPphosphorylation and a significant reduction in CREB-CBP-
TORC2 responsive gene expression.
DISCUSSION
Hepatic gluconeogenesis is essential for the maintenance of
normal blood glucose levels and is tightly regulated by the
opposing actions of insulin and glucagon. Excessive hepatic
glucose production, a characteristic of diabetes mellitus due to
insulin deficiency/resistance and elevated glucagon levels, is
responsible for the fasting hyperglycemia in diabetes. Insulin
counteracts the action of glucagon on hepatic gluconeogenesis
mainly at the transcriptional level through the transcriptional co-
activator PGC-1a (Yoon et al., 2001). The activation of Ppargc1
gene expression by glucagon is mediated by a CREB-CBP-
TORC2 complex (Ravnskjaer et al., 2007). We elucidate here
a mechanism by which insulin and metformin control glucose
production in the liver (Figure 7D). In the gluconeogenic CREB-
CBP-TORC2 complex, CREB is phosphorylated and constitu-
tively occupies the promoter after treatment with either glucagon
or insulin (Figure 4E) (Koo et al., 2005). The binding states of CBP
and TORC2 determine the transcriptional activities of CREB
target genes (Figures 4B and 4G). The phosphorylation of CBP
at Ser436 by insulin and metformin triggers the dissociation of
CBP aswell as TORC2 fromCREB and disassembly of transcrip-
tion machinery. In contrast, while TORC2 phosphorylation
occurred as early as 10 min after insulin treatment, peak phos-
phorylation of TORC2 was not observed until 30 min after treat-
ment at a time when TORC was already completely dissociated
from the promoters (Figure 4G), and consistent with a previous
report (Dentin et al., 2007). After 30 min, insulin further stimulates
the phosphorylation of TORC2 at Ser171 leading to its nuclear
exclusion and degradation (Figures 4E and 7D) (Shaw et al.,
2005; Dentin et al., 2007).
Suppression of gluconeogenesis and hepatic glucose produc-
tion remains an attractive intervention for diabetes mellitus. The
widely prescribed antidiabetic drug metformin lowers blood
glucose levels in diabetes mainly through suppression of hepatic
glucose production (Wiernsperger and Bailey, 1999; Hundal
et al., 2000). It has been proposed that nuclear exclusion of
TORC2 by either insulin or metformin-mediated phosphorylation
is sufficient to terminate the cAMP signaling pathway acting on
gluconeogenic enzyme genes (Koo et al., 2005; Shaw et al.,
2005). However, the O-glycosylation of TORC2 at Ser171 in the
insulin resistant state makes it unable to be phosphorylated
and results in nuclear retention (Dentin et al., 2008). The present
data clearly demonstrate that the triggering event for dissociation
of the CREB-CBP-TORC2 complex is CBP phosphorylation
(Figures 4E, 5D, and 5F). Thus, the effects of insulin and metfor-
min on controlling hepatic glucose production converge on
CBP phosphorylation through aPKCi/l. Atypical PKCi/l plays
a critical role in nutrient metabolism. In the fed state, the activa-
tion of aPKCi/lby insulin phosphorylatesCBPwhich suppresses
gluconeogenesis and increases lipogenesis through the induc-
tion of SREBP-1c (Matsumoto et al., 2003). This also offers
a potential explanation for why a liver-specific knockout of
aPKCi/l in mice had no effect on gluconeogenesis: reduced
hepatic lipid content may have increased insulin sensitivity inCell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc. 643
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Figure 7. High-Fat Diet Induced Insulin Resistance Abolishes Insulin but Not Metformin Mediated CBP S436 Phosphorylation
Mice fed regular or high-fat (60% fat) diet for 4 months were treated with insulin or metformin. (A) In liver tissue from mice fed a high-fat, insulin fails to stimulate
CBP or Akt phosphorylation, whereas metformin maintains CBP phosphorylation capability. Each lane represents an individual mouse sample.
(B) Desitometric analysis of pCBP (Ser436) and pAkt as in (A).
(C) Metformin tolerance test in 16 h fasted mice (n = 3) fed on high-fat diet for 2 months. Means ± SEM are shown (B and C). *, = p < 0.05 as compared to control
mice at each time point.
(D) Proposed model for the regulation of gluconeogenic gene expression by insulin and metformin.thesemice (Matsumoto et al., 2003). In CBP S436Amutant mice,
metformin treatment did not reduce blood glucose levels,
whereas insulin had someeffect (Figure 6F versus6H). This differ-
encemay reflectpathwaysof hepatic insulin signaling, not shared
between metformin and insulin, such as the PI3K-AKT-FOX01
pathway (Kitamura and Accili, 2004; Matsumoto et al., 2007),
as well as direct inhibition of PGC-1a activity by activated AKT
mediated phosphorylation (Li et al., 2007). However, metformin
maintains its ability to lower blood glucose levels in mice even
though these alternate AKT-mediated pathways of insulin
signaling appear to be disturbed following high-fat feeding and
induction of insulin resistance (Figure 7C). Thus, CBP phosphor-
ylation at Ser436 by metformin is critical for its therapeutic effect
and a potential target for pharmaceutical intervention.
EXPERIMENTAL PROCEDURES
Plasmids
The expression vectors for wild-type CBP, CBP mutants (Zhou et al., 2004),
AMPK (Hamilton et al., 2001), and PKA were as described previously (Zhou644 Cell 137, 635–646, May 15, 2009 ª2009 Elsevier Inc.et al., 2004). Mouse WT TORC2, TORC2 S171A and aPKCi/l were cloned
into pcDNA3.1 (Invitrogen). The GFP-TORC2 expression vector was gener-
ated by inserting TORC2 cDNA into pEGFP-N1 plasmid (Clontech). GAL4-
CREB and full-length TORC2 (GAL4-TORC2) were generated using standard
cloning protocols. GAL4-CREB (short, 1–280 aa) was purchased from Strata-
gene. The BLOCK-iT adenoviral RNAi expresson system was used to
construct adenoviral shRNA for CBP and aPKCi/l (Invitrogen).
Cell Cultures and Transfection Assays
Mouse hepatoma H2.35, rat hepatoma H4IIEC3 cells and primary mouse
hepatocytes were exposed to forskolin (10 uM), insulin (10 nM, 10 min), met-
formin (10 mM), AICAR (1 mM), LY294002 (50 uM), Ro31-8220 (20 uM) or
Go6876 (5 uM) as indicated. Lipofectamine 2000 was used in transfection
assays. Equal total amounts of plasmid or RNAi were deployed. Transfections
were repeated in both cell lines, and similar results were observed.
Animal Experiments and Analytical Procedures
All animal protocols were approved by the Institutional Animal Care and Use
Committee of the Johns Hopkins University. CBP S436A mutant mice were
generated as described previously (Zhou et al., 2004). 2- to 6-month-old
mice were maintained on regular chow or high-fat diet. For hepatic CBP phos-
phorylation measurement and metformin tolerance test, mice were injected
intraperitoneally (ip) with 0.5 unit/kg insulin, 200mg/kg metformin or PBS after
fasting for 10–16 hr. Adenoviral shRNA knockdown experiments were con-
ducted 3 days after mice were injected adenovirus through the tail vein. Serum
insulin and glucagon were measured using a mouse endocrine panel kit (Milli-
pore). For the hyperinsulinemic euglycemic clamp experiment, mice were
fasted 18 hr and then [3-3H]-glucose was infused intravenously (2.5 mCi bolus,
0.075 mCi/min). Blood samples (20 ul) were collected at 70, 80, and 90min after
the initiation of 3H-glucose infusion for the measurement of 3H-glucose
specific activity and blood glucose and calculation of basal hepatic glucose
production. Then, regular human insulin was infused at 25 mU/kg/min and
glucose levels were measured every 10 min. An infusion of 25% dextrose
was adjusted to maintain the blood glucose at 100–120 mg/dl. Blood samples
were again collected during the clamp for calculation of hepatic glucose
production.
Immunoprecipitation and Immunoblot
Phospho-Ser436 CBP antiserum was generated against phospho-CBP
peptide containing amino acids 427-445 of mouse CBP protein. All other anti-
bodies, CBP, p300 (Santa Cruz); Akt, phospho-Akt (308), GSK3, phospho-
GSK3, phospho-TORC2, CREB mAb, phospho PKCz/l (Thr410/403), PKCi,
PKCz (Cell Signaling); PKCi kinase (Cell Signaling); AMPK g, TORC2 (Abcam),
phospho-PKC iota (Thr555) (Millipore) were purchased. Immunoprecipitation
(IP) was performed overnight at 4C.
Chromatin Immunoprecipitation
Mice were injected intraperitoneally with insulin, metformin or PBS. Hepatic
tissue was minced and homogenized. The ChIP-IT Express assay kit (Active
Motif) was used following the steps recommended by the manufacturer.
Precipitated DNA was amplified by PCR using primers against relevant mouse
promoters. The PCR cycle number for the input DNA and immunoprecipitates
was optimized to remain in the PCR linear range.
Statistical Analyses
Statistical significance was calculated with an ANOVA test and student’s t test.
Significance was accepted at the level of p < 0.05 or p < 0.01.
SUPPLEMENTAL DATA
Supplemental Data include nine figures and can be found with this article
online at http://www.cell.com/supplemental/S0092-8674(09)00276-1.
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